Key clinical point:
Major finding: The overall response rate was 53%.
Study details: A phase 1 trial involving 30 patients.
Disclosures: Dr. Advani reported receiving research funding from Takeda/Millenium, and serving as a consultant for Pfizer.
Source: Advani A et al. ASH 2017, Abstract 150.
Advani A et al. ASH 2017, Abstract 150.
This Week's Must Reads
CVD Events Prevented with New AHA BP Guideline, Circulation; ePub 2018 Nov 19; Bress, et al
USPSTF: Interventions to Prevent Child Maltreatment, JAMA; 2018 Nov 27; US Preventive Services Task Force
Team-Based Primary Care in Chronically Ill Patients, JAMA Intern Med; ePub 2018 Nov 26; Meyers, et al
Rotating Night Shift Work & Risk of T2D, BMJ; ePub 2018 Nov 21; Shan, Li, et al
PUFAs for Primary & Secondary CVD Prevention, Cochrane Library; ePub 2018 Nov 27; Abdelhamid, et al
Must Reads in Oncology
Does Vitamin D Reduce Cancer & CVD Risk?, N Engl J Med; ePub 2018 Nov 10; Manson, et al
Interventions to Increase CRC Screening Rates, JAMA Intern Med; ePub 2018 Oct 15; Dougherty, et al
Smoking & Lung Cancer Mortality in the US to 2065, Ann Intern Med; ePub 2018 Oct 9; Jeon, et al
Dietary Indexes and Risk of Colorectal Cancer, Am J Clin Nutrit; ePub 2018 Oct 4; Petimar, et al
FIT Performance & Optimal Positivity Thresholds, Ann Intern Med; ePub 2018 Sep 18; Selby, et al